T he risk of thromboembolic complications with the use of hormonal contraception is an important issue scientifically and is relevant for counseling women about contraceptive options. Several studies have assessed the risk of venous thromboembolism associated with the use of newer hormonal contraceptive products, (i.e., those from the past 10 years) 1-8 but few studies have examined thrombotic stroke and myocardial infarction, and the results of available studies have been conflicting. [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] Although arterial complications are less frequent than venous complications among young women, the shortterm and long-term consequences of arterial complications are often more serious.
In addition to oral contraceptive pills and intramuscular injections of depot medroxyprogesterone acetate, the options for hormonal contraception currently include a vaginal ring, transdermal patches, subcutaneous implants, and the levonorgestrel-releasing intrauterine device (IUD; known in Europe as the levonorgestrel intrauterine system). The aim of this study was to assess the risks of thrombotic stroke and myocardial infarction associated with the use of various types of hormonal contraception, according to estrogen dose, progestin type, and route of administration.
ME THODS

STUDY population
We followed an open historical cohort of Danish women, 15 to 49 years old, for a 15-year period, from January 1995 through December 2009. The population was identified on the basis of data from Statistics Denmark. A unique personal identification number that is given to all Danish citizens at birth and to people who have immigrated to Denmark is used in all public registries, allowing reliable linkage of data among different registries. Statistics Denmark also provided data on length of schooling, status of education (ongoing or finished), vital status, and emigration. Data were censored at the time of death or emigration.
Approval for the study was obtained from the Danish Data Protection Agency. Because this was a registry study, the requirement for written informed consent was waived.
END POINTS
Data on clinical end points were obtained from the National Registry of Patients, which has collected discharge diagnoses from public and private Danish hospitals since 1977, and the Register of Causes of Death. The relevant diagnostic codes are listed in Table 1S in the Supplementary Appendix, available with the full text of this article at NEJM .org. We identified thrombotic stroke using the diagnostic code for cerebral infarction (which is used for both cerebral thrombosis and cerebral embolism) and the less-specific diagnostic code for "cerebral apoplexy"; thrombotic events have been found to constitute 80 to 90% of the events in young women that are classified as cerebral apoplexy. [21] [22] [23] Transient cerebral ischemic attack was not included.
To restrict the analysis to first-ever events, we excluded data from all women who had received a diagnosis of any type of venous or arterial thrombotic event before the study period (i.e., from 1977 through 1994). In addition, data from women who had gynecologic, abdominal, breast, lung, or hematologic cancer before the study period were excluded or, if any of these diseases occurred during the study period, were censored at the time of diagnosis (Table 1S in the Supplementary Appendix) .
The National Registry of Patients also records surgical codes from public and private hospitals. Data from women who had undergone bilateral oophorectomy, unilateral oophorectomy two times, hysterectomy, or a sterilization procedure were either excluded at baseline or censored at the time of surgery (Table 1S in the Supplementary Appendix).
Pregnancy outcomes and gestational ages at termination were identified according to the codes specified in Table 1S in the Supplementary Appendix. Data from women were temporarily censored during pregnancy, which was defined as the period from conception through 3 months after delivery (or 1 month after abortion or termination of ectopic pregnancy). Data from women with a coagulation disorder were censored at the recorded date of the initial diagnosis (Table 1S in the Supplementary Appendix) .
Finally, information about smoking habits was obtained from the National Registry of Patients. Information about whether a woman smoked was available for 480,223 women, covering 5.2 million person-years of observation (37% of risk time).
prescriptions for oral contraceptives and other types of hormonal contraception from 1995 through 2009. We categorized the products in use according to estrogen dose, progestin type, and route of administration.
Duration of use was estimated to be the period from the date of the prescription until the end date of the last filled prescription or the date of a study event. Further details regarding the assessment of duration of use are given in a previous report. 6 From the prescription registry, we also obtained updated information about medication for the treatment of diabetes, heart arrhythmia, hypertension, and hyperlipidemia. Data from women with prescriptions for ovarian stimulants were censored at the time that such a prescription was first filled.
STATISTICAL ANALYSIS
Using Poisson regression, we calculated the estimated risks of thrombotic events, with stratification according to estrogen dose (50 μg, 30 to 40 μg, or 20 μg of ethinyl estradiol or progestinonly contraceptive), progestin type, route of administration, and duration of use (<1 year, 1 to 4 years, or >4 years). The reference group comprised nonusers (women who had never used hormonal contraception as well as former users), and the estimates of relative risk were adjusted for age, calendar year, length of schooling, educational level (ongoing or completed), and status with respect to hypertension, heart disease, diabetes, and hyperlipidemia (defined by the use or nonuse of medications for these conditions). Imputed values for missing data on smoking status were calculated with the use of standard procedures of imputation, 24 and sensitivity analyses that included imputation for smoking status were conducted (Table 2S in the Supplementary Appendix).
Tests for interactions of the different types of hormonal contraception with age and with predisposing diseases were conducted. Sensitivity analyses in which only the specific code for cerebral infarction, DI63, was included were performed for all product types. Finally, sensitivity tests were 
R E SULT S
THROMBOTIC EVENTS IN THE STUDY COHORT
After the exclusion and censoring of data as specified in Figure 1 , the study cohort included and use or nonuse of hormonal contraception, the incidence rates of thrombotic stroke and myocardial infarction were increased by factors of 20 and 100, respectively, in the oldest age group (45 to 49 years) as compared with the youngest age group (15 to 19 years) ( Table 1 ). Women with the highest level of education had about half as many thrombotic strokes and about one third as many myocardial infarctions as women with the lowest level of education ( Table 1) . The relative risks of thrombotic stroke and myocardial infarction, respectively, among women who filled prescriptions for medications to treat predisposing disorders, as compared with women who did not fill prescriptions for these medications, were as follows: for diabetes, 2. 
HORMONAL CONTRACEPTION AND ARTERIAL THROMBOSIS
In 4.9 million person-years of use of hormonal contraception, 1051 women had a thrombotic stroke and 497 had a myocardial infarction; the crude incidence rates were 21.4 and 10.1 per 100,000 person-years, respectively. The corresponding incidence rates in 9,336,662 person-years of nonuse, during which 2260 women had a thrombotic stroke and 1228 had a myocardial infarction, were 24.2 and 13.2 per 100,000 person-years, with the higher rates primarily due to older age and a higher frequency of predisposing conditions among nonusers ( Table 2 ). The risk among previous users was similar to the risk among women who had never used hormonal contraception. The rate ratio for thrombotic stroke among previous users, as compared with women who had never used hormonal contraception, was 1.04 (95% CI, 0.95 to 1.15), and for myocardial infarction, 0.99 (95% CI, 0.86 to 1.13).
After stratifying the data for current users of hormonal contraception according to estrogen dose, progestin type, and route of administration, we estimated the crude incidence rates and adjusted relative risks of thrombotic events for users as compared with nonusers ( Table 2 ). The estimated relative risks of thrombotic stroke and myocardial infarction among users of combined oral contraceptive pills that included ethinyl estradiol at a dose of 30 to 40 μg did not differ significantly according to the type of progestin, ranging from 1.40 to 2.20 for stroke and from 1.33 to 2.28 for myocardial infarction. For both end points, the risk estimates were lowest with contraceptive pills that included norgestimate or cyproterone acetate and were highest with those that included norethindrone or desogestrel (Table 2) .
For women who used desogestrel with a reduced dose of ethinyl estradiol (20 μg), as compared with nonusers, the relative risks of thrombotic stroke and myocardial infarction were 1.53 (95% CI, 1.26 to 1.87) and 1.55 (95% CI, 1.13 to 2.13), respectively. For women who used drospirenone with ethinyl estradiol at a dose of 20 μg, the relative risk of thrombotic stroke was 0.88 (95% CI, 0.22 to 3.53); there were no myocardial infarctions in this group. None of the progestin-only products, including the levonorgestrel-releasing IUD and the subcutaneous implants, significantly increased the risk of thrombotic stroke or myocardial infarction (Table 2 ), but the numbers were small for several of these groups. In contrast, the relative risk of thrombotic stroke was 3.15 (95% CI, 0.79 to 12.6) among women who used contraceptive patches and 2.49 (95% CI, 1.41 to 4.41) among those who used a vaginal ring. Numbers of myocardial infarctions were too low to provide reliable estimates.
An analysis adjusted for differences in progestin type, age, and calendar year showed that combined oral contraceptives with doses of ethinyl estradiol of 20 μg, 30 to 40 μg, and 50 μg were associated with a relative risk of thrombotic 
sensitivity analyses
There was no consistent interaction between the use of oral contraceptives and the relative risk of thrombotic stroke or myocardial infarction in different age groups, and there were no trends according to duration of use for either end point ( Table 3 ). The sensitivity analysis, which included only women with the diagnostic code for cerebral infarction, provided slightly higher risk estimates than our primary analysis of thrombotic stroke (Table 3S in the Supplementary Appendix). Although the incidence rate of thrombotic stroke increased over time, we could not detect any consistent change in the estimated relative risks of the two end points for four different product groups during the three periods of 1995 through 1999, 2000 through 2004, and 2005 through 2009 (data not shown). We found no interaction between the use of hormonal contraception and predisposing disease for the risk of thrombotic stroke or myocardial infarction. The age distribution according to product group is shown in Figure 2S in the Supplementary Appendix.
DISCUSSION
The rates of thrombotic stroke and myocardial infarction increased by factors of 20 and 100, respectively, with increasing age. Only small differences in risk were observed between women who took combination pills containing intermediatedose ethinyl estradiol (30 to 40 μg) and those who took low-dose ethinyl estradiol (20 μg), and only minor variations in risk were associated with different progestin types. The increased incidence of thrombotic stroke over the 15-year study period probably reflects improvements in the diagnostic equipment, allowing the detection of small cerebral infarctions, rather than a real increase in incidence. The steep increase in incidence with older age has been shown in several previous studies. [9] [10] [11] 25 This information has clinical implications, given that arterial thrombosis after the age of 30 years is more frequent and has more serious consequences than venous thrombosis. 6 The risk of arterial thrombosis should therefore be considered together with the risk of venous thrombosis when hormonal contraception is prescribed.
The relative risk of thrombotic stroke of 1.4 to 2.2 among current users of oral contraceptives containing ethinyl estradiol at a dose of 30 to 40 μg is slightly lower than previously reported (Table 4S in the Supplementary Appendix). In a multicenter World Health Organization study, Poulter et al. found that women who used secondgeneration oral contraceptive pills with levonorgestrel, as compared with nonusers, had a relative risk of thrombotic stroke of 2.7 (95% CI, 1.8 to 4.1) and users of third-generation pills had a relative risk of 1.8 (95% CI, 0.6 to 5.2). 9 Among women who had their blood pressure measured before obtaining a prescription, these risk estimates were reduced to 2.0 (95% CI, 1.1 to 3.6) and 1.6 (95% CI, 0.4 to 6.6), respectively. 9 These estimates are closer to ours, perhaps because a majority of Danish women have their blood pressure checked before obtaining prescriptions for oral contraceptives.
In our secondary analysis, which included only the code for cerebral infarction, we observed a slightly higher relative risk of stroke associated with hormonal contraception, as compared with our primary analysis. This difference may have been due to the inclusion of 15 to 20% of hemorrhagic strokes in the primary analysis that were coded as cerebral apoplexy, supporting the finding that oral contraception is associated with a lower risk of cerebral hemorrhage than of cerebral infarction. [26] [27] [28] Heinemann et al. reported a case-control study showing that women who used second-generation oral contraceptive pills with levonorgestrel or norgestimate had a risk of thrombotic stroke that was 2.7 times (95% CI, 1.5 to 4.6) as high as the risk among nonusers and those who used third-generation pills had a risk that was 3.4 times (95% CI, 1.9 to 6.4) as high. 10 These estimates are higher than those reported in the present study.
In a previous Danish case-control study that covered the period from 1994 through 1998, we found that users of second-generation oral contraceptive pills had a risk of cerebral thromboembolism that was 2.2 times (95% CI, 1.6 to 3.0) as high as the risk among nonusers. 11 The odds ratio for cerebral thromboembolism among users of third-generation pills was 1.4 (95% CI, 1.0 to 1.9). These results are in accordance with our current findings.
Gronich et al. recently found that oral contraceptives with drospirenone and ethinyl estradiol at a dose of 30 μg were associated with the same magnitude of risk as second-generation and thirdgeneration pills with the same dose of estrogen 8 -results that are in agreement with ours. Our data suggest a relatively high risk of thrombotic stroke with the use of a vaginal ring and possibly with the use of transdermal patches. Until further evidence emerges, one might expect a higher risk of thrombotic stroke with parenteral administra- tion than with oral administration (estrogen combined with progestin). There was a relatively high correlation in risk estimates for thrombotic stroke and myocardial infarction among the different product groups -a finding that increases the likelihood that the observed differences in risk were real rather than random variations. One previous study showed a tendency toward a higher relative risk of myocardial infarction with the use of third-generation, as compared with second-generation, oral contraceptives, 16 three showed the opposite result, 13, 14, 19 and one showed no difference 18 (Table 4S in the Supplementary Appendix). We found no consistent difference according to progestin type, but the risk decreased with lower doses of estrogen. We also found that low-dose pills were associated with approximately a 50% increase in the risk of myocardial infarction and intermediate-dose pills with up to a 100% increase in risk.
A crucial point in all registry-based studies is the validity of the diagnostic codes. In our 2002 study, we excluded 5.0% of women with a diagnosis of thrombotic stroke because of an absence of confirmation from the patient or the treating department. 11 The diagnosis of myocardial infarction has been found to be valid in 93.6% of patients of all ages, 29 and the percentage is probably higher among young patients. Any diagnostic misclassification may have led to an underestimation of the relative risks among current users. Another limitation is that, for some women, there may have been a time lag between the date of the prescription and the date the medication was actually started.
We had detailed and valid exposure information because the prescriptions were transferred electronically from the pharmacies by bar codes linked to the personal identification number. We were thus free of recall bias, an issue of concern in all retrospective case-control studies. The national cohort design ensured a large sample and allowed the calculation of risk estimates for specific product groups according to estrogen dose, progestin type, and route of administration -the majority with an acceptable precision. The design also avoided the problem of sample reduction due to nonresponse in survey studies, ensuring a high external validity.
For the levonorgestrel-releasing IUD, we had information only about the dates that the women received the IUD. Although this IUD has a valid period of 5 years, many women have it removed before the expiration date. Because of this uncertainty, we censored data for women with a levonorgestrel-releasing IUD after 3 years, unless another prescription for hormonal contraception was filled before that date. This approach reduced our exposure time for this specific product but increased the probability that the women who were classified as having a levonorgestrel-releasing IUD actually did have it.
Data on body-mass index were not available, but body-mass index was not a confounder in our previous study. 11 Smoking, although an important risk factor for arterial thrombosis, had no confounding influence in either this study or our previous one, in which we had more comprehensive information about this potential confounder. Therefore, it is not likely that our results were strongly influenced by incomplete data on these two potential confounders. However, in the absence of definitive data, we cannot be sure whether there would be an interaction with smoking.
In conclusion, women who used oral contraceptives with ethinyl estradiol at a dose of 30 to 40 μg had a risk of arterial thrombosis that was 1.3 to 2.3 times as high as the risk among nonusers, and women who used pills with ethinyl estradiol at a dose of 20 μg had a risk that was 0.9 to 1.7 times as high, with only small differences according to progestin type. We estimate that among 10,000 women who use desogestrel with ethinyl estradiol at a dose of 20 μg for 1 year, 2 will have arterial thrombosis and 6.8 women taking the same product will have venous thrombosis. Although venous thrombosis is three to four times as frequent as arterial thrombosis among young women, the latter is associated with higher mortality and more serious consequences for the survivors. Therefore, these figures should be taken into account when prescribing hormonal contraception.
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